Biotech pioneer Neovii under new management

Sebastian Hofmann (links) übernimmt die Geschäftsführung der Neovii Biotech GmbH von CEO Dr. Christian Loss (rechts)

Dr. Christian Loss (57), former managing director of Neovii Biotech GmbH, Gräfelfing, is moving to the Swiss headquarters of Neovii Pharmaceuticals AG in Rapperswil as chief executive officer (CEO). As the new CEO in Germany, he will be succeeded by the former Neovii Head of Production, Sebastian Hofmann (40). With the change in management, two long-serving and experienced employees remain with the company: each have been with the company for more than ten years. Their joint mission is to further increase Neovii’s momentum. “We have been on the market for 40 years, making us one of the pioneers in the biotech scene in Europe,” says Dr. Loss. “Today, biotechnology is one of the key technologies of the 21st century – at Neovii, it has always been the basis for producing Grafalon.” Grafalon is an immunosuppressive pharmaceutical used to prevent acute organ transplant rejection. It is also indicated for prevention after stem cell transplantation to protect against graft-versus-host disease (GVHD). Since its development, the pharmaceutical has been continuously refined in line with medical progress and for the benefit of patients.

Global Player from Gräfelfing near Munich

The new managing director of Neovii Biotech GmbH in Germany, Sebastian Hofmann, points to Neovii’s significant role in biopharmaceuticals: “With a comparatively small team of around 150 colleagues, we are one of the two global players in the GVHD prevention market.” This speaks to the dynamism and innovative power at Neovii. The team of researchers and specialists is currently working to further expand the medical use of the product in the field of transplantation, hemato-oncology and immune diseases. To this end, the expansion of the production site in Gräfelfing is being driven forward: “We are growing at the site, expanding production capacities. The next construction phase has already been coordinated with the local authority,” says Hofmann. While manufacturing and research and development are based in Gräfelfing, medical development and internationalization are being driven forward from the Swiss headquarters. The focus is on obtaining approval by U.S-FDA.

Furthermore, the presence in additional territories is to be expanded. Dr. Loss: “With our team, decades of experience in clinical development and regulatory affairs, and our top technology platform, we are now taking the next step to become one of the leading biopharmaceutical companies in the global treatment of severe immune and cancer diseases.”